Lantheus Holdings, Inc. Announces Robust Financial Results for 2024
Lantheus Holdings, Inc. has reported remarkable financial performance for the fourth quarter and full year of 2024. This leading radiopharmaceutical company has generated worldwide revenues of $391.1 million in Q4 and $1.53 billion for the entire year. Lantheus is dedicated to enabling healthcare providers in their quest to diagnose, treat, and manage diseases effectively, which is reflected in their impressive results.
Free Cash Flow and Earnings Performance
In the last quarter, Lantheus achieved free cash flow of $141.4 million, with an overall cash flow of $493.1 million for the entire year. The company’s GAAP fully diluted loss per share was $(0.17), while they reported earnings per share of $4.36. Adjusted fully diluted earnings per share for the fourth quarter stood at $1.59, demonstrating a dedicated effort to provide significant value to their shareholders.
Milestones Achieved with PYLARIFY
One of the standout achievements for Lantheus in 2024 was the net sales of PYLARIFY, which exceeded $1 billion, making it the first-ever blockbuster in the radiodiagnostic market. This substantial achievement underscores the impact of innovative radiopharmaceutical solutions on patient outcomes and the recognition of PYLARIFY's effectiveness in clinical settings.
Strategic Growth Initiatives for 2025 and Beyond
Going forward into 2025, Lantheus aims to diversify its portfolio through strategic asset acquisitions and licensing deals. These efforts are designed to expand their reach and enhance their offerings in both early- and late-stage clinical assets. CEO Brian Markison emphasized their vision for sustainable growth in high-potential markets, which will enhance shareholder value considerably.
Financial Guidance and Projections
The company provided a full-year guidance for revenue expectations, projecting a revenue range of $1.545 billion to $1.610 billion for 2025, alongside an adjusted fully diluted earnings per share anticipated between $7.00 and $7.20. This outlook highlights Lantheus's commitment to generating robust financial results while continuously enhancing their market position.
Recent Business Highlights and Developments
In 2024, Lantheus embarked on multiple strategic transactions adding five new assets to their pipeline. They acquired global rights for Life Molecular Imaging's RM2, targeting critical receptors related to cancer, and also enhanced their Alzheimer's disease diagnostic pipeline through the acquisition of NAV-4694.
Additionally, Lantheus has entered into strategic agreements aimed at bolstering its comprehensive radiopharmaceutical capabilities, thus reinforcing its position as a leader in the industry.
Looking Ahead at Regulatory Updates
The Centers for Medicare & Medicaid Services (CMS) has recently included provisions for separate payment for specialized diagnostic radiopharmaceuticals under its new Medicare rules for 2025, which is expected to further support access to innovative products like PYLARIFY. This regulatory change reflects the importance of these advancements in improving patient outcomes and ensuring innovations within the healthcare sector are accessible.
Company Overview
Lantheus Holdings, Inc. is dedicated to developing innovative radiopharmaceutical solutions that enhance the diagnostic and therapeutic capabilities of healthcare providers. With a commitment to science-backed solutions, Lantheus is positioned for sustainable growth within the rapidly evolving healthcare landscape.
Contact Information
For further inquiries, contact:
Mark Kinarney
Vice President, Investor Relations
978-671-8842
ir@lantheus.com
Melissa Downs
Senior Director, External Communications
646-975-2533
media@lantheus.com
Frequently Asked Questions
What were the total revenues for Lantheus in 2024?
Total revenues were reported at $1.53 billion for the full year 2024.
How much cash flow did Lantheus generate in 2024?
Lantheus generated a free cash flow of $493.1 million for the full year 2024.
What is PYLARIFY's significance in the market?
PYLARIFY became the first-ever blockbuster radiodiagnostic, surpassing $1 billion in net sales.
What is Lantheus's projected revenue for 2025?
The projected revenue for 2025 is estimated to be between $1.545 billion and $1.610 billion.
How many new assets were added to Lantheus's pipeline in 2024?
Lantheus added five new assets to its pipeline in 2024 through strategic transactions.
